Your Kidneys and Your Diabetes: What You Need to Know Before It's Too Late
- t2diabetesnetwork
- Jun 23
- 3 min read
Written by Clare Koning, RN, PhD June 2026 5 min read
Key Highlights
✅ Diabetic kidney disease affects approximately 1 in 4 people with T2D
✅ It is largely silent until significant damage has occurred
✅ SGLT2 inhibitors have revolutionized kidney disease treatment
✅ Guidelines recommend earlier initiation of kidney-protective medications
✅ A simple urine test and blood creatinine check can detect early kidney involvement
Of all the complications of type 2 diabetes, diabetic kidney disease is perhaps the quietest. It produces no pain, no visible signs, and often no symptoms at all until kidney function has declined substantially. Yet it is the single leading cause of kidney failure requiring dialysis in Canada, and it affects approximately one in four people with T2D.
The clinical landscape around diabetic kidney disease has changed dramatically in the past five years, with new medications, updated guidelines, and a fundamental shift in how providers approach kidney protection in T2D. Here is what you need to know.
How Diabetes Damages the Kidneys
The kidneys contain millions of tiny filtering units called glomeruli, each fed by a network of capillaries. Chronic high blood sugar damages these capillaries in two ways: first, by causing direct glycation damage to the capillary walls; second, by increasing pressure within the glomeruli (hyperfiltration), which forces the filters to work harder and accelerates their deterioration.
The first detectable sign of this damage is usually microalbuminuria, the appearance of small amounts of the protein albumin in the urine, indicating that the kidney filter is becoming leaky. As damage progresses, protein loss increases, blood pressure typically rises, and the estimated glomerular filtration rate (eGFR), which measures how efficiently the kidneys are filtering blood, begins to fall.
The 2026 ADA Standards of Care recommend annual screening for all people with T2D, beginning at diagnosis, using both a urine albumin-to-creatinine ratio (uACR) and an eGFR blood test. The combination of these two simple tests provides an early warning system that most people with T2D are entitled to but not all routinely receive.
The SGLT2 Revolution
The most significant development in diabetic kidney disease management in recent years has been the emergence of SGLT2 inhibitors, including dapagliflozin (Forxiga) and empagliflozin (Jardiance), originally approved as glucose-lowering medications, as kidney-protective agents in their own right.
Landmark randomized trials including DAPA-CKD and EMPA-Kidney demonstrated that SGLT2 inhibitors significantly reduce the risk of kidney disease progression and kidney failure in people with chronic kidney disease, with benefits seen whether or not participants had diabetes. In trials specifically focused on diabetic kidney disease, SGLT2 inhibitors reduced the risk of a sustained decline in kidney function by approximately 50% compared with placebo, a magnitude that has prompted a fundamental reassignment of these drugs from glucose-lowering agents to cardiorenal-protective agents.
The mechanism goes beyond glucose control. SGLT2 inhibitors reduce intraglomerular pressure, the harmful elevated filtration pressure that drives chronic kidney disease (CKD) progression in diabetes, through a hemodynamic effect on the glomerular afferent arteriole. They also reduce inflammation, reduce body weight, lower blood pressure, and appear to protect kidney tubular cells directly from metabolic stress.
Let's pause on that... SGLT2 inhibitors reduce kidney disease progression by approximately 50% in people with diabetic CKD. That is a remarkable clinical result for a class of drugs that was originally approved purely for blood sugar.
This Harvard Medical School Continuing Education video examines these key questions: How do SGLT2 inhibitors provide kidney protection? What key findings in CREDENCE and DAPA-CKD, two landmark kidney outcomes trials, have led to new SGLT2i guidelines for patients with CKD?
Updated 2026 Guidelines
The 2026 ADA Standards of Care include new guidance on glucose-lowering therapies in people with chronic kidney disease, including use by those on dialysis, reflecting a continued expansion of the kidney-protective treatment framework. Importantly, the guidelines now support initiating SGLT2 inhibitors at earlier stages of CKD than previously recommended, extending kidney protection to more people with T2D.
The 2026 guidelines also highlight finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, as an additional kidney and heart-protective agent in T2D-associated CKD, based on the FIDELIO and FIGARO trials showing reduced risk of kidney failure and cardiovascular events.
What People with T2D Should Ask Their Provider
If you have T2D and have not recently had your kidneys checked, ask for both a urine albumin test and a blood creatinine/eGFR at your next appointment. These are standard of care and should be done annually.
If you are already on an SGLT2 inhibitor for blood sugar control, your kidneys are likely already benefiting. If you are not, and have any degree of kidney involvement, ask your provider whether you are a candidate.
Early detection and treatment is the difference between slowing this condition and arresting it before serious harm occurs.
For more on managing diabetes complications, visit the T2D Network's Monitoring & Medication and Learn More pages.
